';
CLOSE
Tags Posts tagged with "DDAP"

DDAP

0 4353

Beginning June 9, 2022, the Pennsylvania Department of Drug and Alcohol Programs (DDAP) will have the authority to impose fines on operators of unlicensed recovery houses that receive public funding.

View the Recovery House Licensure Information Bulletin here.

DDAP’s recovery house licensure program is live as of December 11, 2021. You can learn more about recovery house licensing and how to apply on the DDAP licensing web page. This message is to remind all recovery houses in Pennsylvania, as well as entities who refer individuals to recovery houses, of several requirements of the Recovery House Law (Act 59 of 2017), including the approaching June 9 deadline.

Requirements to Obtain a License:

Recovery houses must obtain a license from DDAP if:

  1. They are receiving federal or state funding;
  2. They are receiving referrals from publicly-funded facilities; and/or
  3. They are receiving referrals for individuals whose substance use disorder (SUD) treatment is funded with federal or state funding.

*Recovery houses that are not required to obtain a license may still choose to do so.

Referral Requirements:

  • State or county courts must give first consideration to recovery houses that are licensed by DDAP when making residential recommendations for individuals under their supervision.
  • Treatment providers making recovery house referrals for publicly-funded clients must refer to recovery houses that are licensed by DDAP.
  • Any state agency or state-funded facility making recovery house referrals must refer to recovery houses that are licensed by DDAP. A “state-funded facility” is any facility that receives any type of funding from a state agency. For example, this may include an SUD treatment facility that receives funding from their Single County Authority, Managed Care Organization, or a grant from a state agency. It also includes state and state-funded agencies that make referrals for residential settings, such as the criminal justice, juvenile justice, and child welfare systems.

Names, locations, and additional details about each DDAP-licensed recovery house in Pennsylvania are regularly updated on DDAP’s Facility Locator. Select “Recovery House” under the Facility Type Search drop-down on the left-hand panel, and narrow your search by location if desired. A searchable map will also be made available on the DDAP website in the coming weeks.

Fines for Unlicensed Recovery Houses That Receive Public Funds:

Furthermore, the recovery house law requires that DDAP impose fines (up to $1,000 for each violation) on unlicensed recovery houses that are “funded, in whole or in part, by a department or a Federal, other State, or county agency.” This requirement was incorporated in the regulations at 28 Pa. Code § 717.14. As detailed in the Preamble to the regulations, this section will become effective 180 days after publication of the regulations in the Pennsylvania Code & Bulletin on December 11, 2021. Beginning June 9, 2022, DDAP will have the authority to impose fines up to $1,000 per day on operators of unlicensed recovery houses that receive public funding.

Training:

To further assist recovery home operators in the application process, the Bureau of Program Licensure offers a free one-day training workshop designed to answer the various questions associated with the application process. Participation in the workshop results in a decrease in the amount of time it takes to approve applications, resulting in the license being issued sooner to those applicants who participate. The workshop is offered a minimum of once every month. Additional sessions are scheduled based upon interest or need. Requests to register for the training should be sent via email. Call 717-783-8675 with questions.

0 1422

Since 2017, Pennsylvania has taken several steps to increase naloxone access for people and communities across the commonwealth who need it the most. With a recent increase in drug overdose deaths (the majority of which are opioid- and fentanyl-related), Pennsylvania is anticipating a significant supply of naloxone in the coming months. The Department of Drug and Alcohol Programs is encouraging individuals, organizations, and agencies to learn how to access this naloxone at no cost.

0 4045

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) has launched the Substance Use Disorder (SUD) Loan Repayment Program (LRP). This program will aid SUD treatment and Single County Authority (SCA)-funded case management professionals in repaying their outstanding qualifying educational loans.

Applications must be submitted via the online application portal by May 26, 2022. Eligible practitioners must have the capacity to provide SUD treatment or SCA-funded case management services at approved practice site(s) and meet the requirements in Section 6 of the Project Summary. Selected candidates must demonstrate a minimum of two prior years of experience in the SUD field as well as agree to a service commitment of two additional years.

For more information, view the Application Guidance. Questions regarding the grant and the application process can be emailed to DDAP.

0 1530

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) is highlighting the increased prevalence of alcohol misuse, alcohol use disorder (AUD), and available treatment options during National Alcohol Awareness Month.

According to the National Institute on Alcohol Abuse and Alcoholism (NIAA), an estimated 95,000 people die from alcohol-related causes annually, making alcohol the third-leading preventable cause of death in the United States. The NIAA also reports that less than 4 percent of people with AUD were prescribed a medication approved by the U.S. Food and Drug Administration to treat their disorder. Additionally, DDAP data shows that treatment admissions for alcohol as the primary substance accounted for almost 33 percent of all treatment admissions across Pennsylvania last year.

Read the press release for information on treatment resources.

0 1709

Yesterday, the Department of Drug and Alcohol Programs’ (DDAP) Secretary Jen Smith virtually joined Pennsylvania Attorney General Josh Shapiro, Butler County Commissioner and County Commissioners Association of Pennsylvania Board Chairman Kevin Boozel, and Berks County Council on Chemical Abuse to discuss the incoming opioid settlement funding in Pennsylvania.

Read the press release.

0 1446

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) released Information Bulletin 01-22 today. The purpose of the bulletin is to remind all recovery houses in Pennsylvania, as well as entities who refer individuals to recovery houses, of several requirements of the recovery house law (Act 59 of 2017). A letter from DDAP Secretary Jennifer Smith communicating details of the bulletin was issued today to all stakeholders, as well.

0 2176

With Senate Bill 1019 passed into law as Act 14, the Department of Drug and Alcohol’s (DDAP) regulatory suspensions are also extended. These regulatory suspensions are “related to federal exemptions granted under the federal public health emergency declaration” until “the last day federal exemptions granted under the federal public health emergency declaration are authorized.” In addition to three DDAP regulatory suspensions, one additional regulation from the Department of State, also relevant to the field, is included in the chart below and also remains suspended.

Statute/Regulation Statute/Regulation Purpose

Waiver Benefit/Explanation

28 Pa. Code § 715.16(e)

 Prohibits narcotic treatment programs (NTPs — methadone clinics) from permitting a patient to receive more than a 2-week take-home supply of medication In response to COVID-19, SAMHSA is allowing up to 28 days of take-home medications for patients on stable dosages, if the physician deems appropriate.
28 Pa. Code § 715.9(a)(4) Requires NTPs to make a face-to-face determination before admission to treatment, for those clients who will receive buprenorphine treatment. In response to COVID-19, SAMHSA is allowing initial evaluations for a patient who will be treated with buprenorphine to be completed via telehealth.
28 Pa. Code § 715.6(d) Requires NTPs to have narcotic treatment physician services onsite. In response to COVID-19, SAMHSA is allowing initial evaluations for a patient who will be treated with buprenorphine to be completed via telehealth.
49 Pa. Code § 16.92(b)(1)

(Department of State)

 Before a patient can be prescribed any controlled substance in Pennsylvania, a person licensed to practice medicine and surgery in the commonwealth, or otherwise licensed or regulated by the State Board of Medicine, must take an initial medical history and conduct an initial physical examination, unless emergency circumstances justify otherwise.

In response to COVID-19, the Department of State suspended the initial medical history and physical examination requirement specifically for the treatment of opioid-use disorder with buprenorphine.

 

In November 2021, the Substance Abuse and Mental Health Services Administration (SAMHSA) announced that the methadone take-home flexibilities will be extended for one year after the eventual expiration of the federal COVID-19 Public Health Emergency. DDAP has submitted its written concurrence with this exemption. SAMHSA has also indicated that they are currently considering mechanisms to make this flexibility permanent. Narcotic treatment programs do not need to do anything additional at this time to continue taking advantage of this flexibility.

Similarly, the U.S. Drug Enforcement Administration (DEA) also announced last week that they are currently working to make their teleprescribing regulations permanent. DDAP will continue to provide additional information and guidance as it becomes available.

If you have any further questions, please contact the Bureau of Program Licensure at (717) 783-8675 or via email.

0 1916

With this week’s signing of the federal Consolidated Appropriations Act of 2022, the Pennsylvania Department of Drug and Alcohol Programs (DDAP) expects its budget for Fiscal Year (FY) 2023 to be at least equal to the current year’s budget of $378 million. Before the signing of the act, DDAP’s budget was $317 million. The difference was the result of a $60 million gap in a state opioid response (SOR) grant that has been restored. The majority of DDAP’s funding comes from the federal government, as opposed to state dollars.

As part of the Federal Appropriations Act, $3.9 billion has been budgeted for substance use treatment, including continued funding for opioid prevention and treatment, recovery, and tribal focused treatment efforts. This includes $1.85 billion for the Substance Abuse Prevention and Treatment Block Grant (SABG); $1.525 billion for SOR Grants; $34.9 million for Pregnant & Postpartum Women; $13 million for Building Communities of Recovery; and $101 million for Medication Assisted Treatment.

In its Senate Appropriations Hearing yesterday, DDAP said that, although the exact amount of Pennsylvania’s SOR grant for FY 2023 was not yet know, it expected it to be at least as much as the current year’s grant, which is $178 million.

0 1631

The Senate Appropriations Committee will meet for a budget hearing with the Department of Drug and Alcohol Programs (DDAP) at 2:30 pm today, March 16. The budget hearing will be livestreamed. Please note that RCPA provider members received an email from RCPA earlier this week that incorrectly stated the hearing was at 10:00 am today.

For Fiscal Year 2022/2023, the governor is budgeting a total of $317 million for DDAP, which is a 16 percent reduction over the current fiscal year’s budget of $379 million. The decrease is due to a $60 million reduction in federal State Opioid Response dollars.

More details of DDAP’s budget are available in DDAP’s Bluebook. In addition, a previous communication from RCPA about DDAP’s budget ahead of its House Appropriations Committee provides additional detail about the $317 million budget.

Prev1...131415Next Page 14 of 15
© 2021 - Rehabilitation & Community Providers Association